Vertex Pharmaceuticals (VRTX) Revenue (2009 - 2026)

Vertex Pharmaceuticals has reported Revenue for 18 years, with the latest figure at $3.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 7.82% year-over-year to $3.0 billion; the trailing twelve-month figure through Mar 2026 stood at $12.2 billion (up 10.08% YoY), and the FY2025 full-year result was $12.0 billion, up 8.9% from the prior year.
• Revenue for Q1 2026 stood at $3.0 billion, down from $3.2 billion in the prior quarter.
• The five-year high for Revenue was $3.2 billion in Q4 2025, with the low at $2.1 billion in Q1 2022.
• Average Revenue over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2024.
• Year-over-year, Revenue rose 22.46% in 2022 and increased 2.96% in 2025.
• Tracing VRTX's Revenue over 5 years: stood at $2.3 billion in 2022, then climbed by 9.34% to $2.5 billion in 2023, then grew by 15.66% to $2.9 billion in 2024, then grew by 9.55% to $3.2 billion in 2025, then decreased by 6.37% to $3.0 billion in 2026.
• The last three Revenue figures came in at $3.0 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.1 billion (Q3 2025), per Business Quant data.

Peer Comparison